Synosis: the Financial Leverage of Translational Medicine
This article was originally published in Start Up
Executive Summary
Biotech investors have struggled with the fact that it takes take years, hundreds of millions of dollars, and widely varying sets of expertise to create a product. For Synosis, the answer is translational medicine: it starts life with nine compounds from three European companies, aiming to figure out the best indications and dosing for each, prove them through Phase II, and then out-license them.
You may also be interested in...
Institutionalizing Externalization At Big Pharma – The Third Leg
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
Synosia Reworks Roche Deal To Take On Alzheimer’s/Schizophrenia Candidate
Privately held Swiss biotech thinks 5-HT6 antagonists could offer superior targeting and side-effect profiles.
Synosia Reworks Roche Deal To Take On Alzheimer’s/Schizophrenia Candidate
Privately held Swiss biotech thinks 5-HT6 antagonists could offer superior targeting and side-effect profiles.